National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cabozantinib (Cabometyx®) is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

 

Rapid Review

Commenced Completed Outcome
20/03/2017 25/04/2017 Full Pharmacoeconomic Evaluation Recommended